In a 34-year-old patient toxoplasma retinitis/ encephalitis developed 9 months after bone marrow transplantation. The BMT was complicated with a serious GVHD. Although she initially responded well to antibiotic therapy she died 2 years after BMT due to progressive infection.
Reactivation of latent toxoplasmic infection is a well described disease entity in the immunocompromised host. Its occurrence has only occasionally been described in immunodeficient patients not being related to AIDS. 1 The number of reported cases in bone marrow transplant (BMT) recipients does not exceed 50 [1] [2] [3] and in nearly all cases the infection occurred within 6 months after transplantation.
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Case report
In February 1994, a 34-year-old woman was found to have a high-grade lymphoblastic B cell non-Hodgkin's lymphoma, stage IV-B. She was treated to complete clinical remission with intensive chemotherapy, including intrathecal administration of methotrexate as CNS prophylaxis. After conditioning chemotherapy and total body irradiation an allogeneic BMT was performed in September 1994 with T cell-depleted bone marrow from her HLA-A, B, DRidentical, MLC-negative sister. The patient was then IgG seropositive for Toxoplasma gondii, the donor negative. From day 0 of BMT, immunosuppressive therapy with cyclosporin A was given. After 6 weeks trimethoprimsulphamethoxazole as Pneumocystis carinii pneumonia prophylaxis was switched to aerolized pentamidine because of presumed skin toxicity.
Soon after BMT acute graft-versus-host disease (GVHD) of the skin developed. The immunosuppressive therapy was intensified, but chronic GVHD evolved. The severity of the GVHD was inversely dose-related to the intensity of the immunosuppression given. In March 1995, herpes stomatitis (HSV-I) was treated with a 4-week course of foscarnet, since there was resistance to acyclovir.
In April 1995 (7. months post-BMT) she complained of episodic headaches and underwent neurologic evaluation. No specific diagnosis, however, could be made. Cerebrospinal fluid analysis was unremarkable and electroencephalography (EEG) showed only mild diffuse slowing, which was thought to be due to the chemotherapy given. In the second half of June 1995 (more than 9 months post-BMT) mental disturbances were noted by her husband and soon thereafter she rapidly lost her sight. On physical examination she ran a fever of 38.7°C. She was lethargic and disorientated in time. Marked hypotonia was noted, but meningeal signs were lacking, as were focal signs. Tendon reflexes were lowered. Plantar reflexes were flexor. Ophthalmologic examination revealed a visual acuity of 0.125 in the right eye and 3/60 in the left; fundoscopy showed a severe necrotizing retinitis with a vitreous inflammatory reaction in both eyes. Cerebral computer tomography (CT) with intravenously administered contrast showed diffuse edema without focal abnormalities. EEG revealed marked diffuse slowing, as well as hypofunction and irritative disturbances in both temporal regions. CSF analysis showed a pleiocytosis of 19 white cells/l, 0.49 g/l protein, and 3.0 mmol/l glucose. Since herpes simplex strains were again isolated from the oral cavity, a presumptive diagnosis of herpes encephalitis/retinitis was made and treatment with foscarnet was restarted. CSF culturing, however, did not demonstrate any viral infection and even PCR analyses did not expose any infection with herpes simplex virus (HSV), cytomegalovirus (CMV) or Toxoplasma gondii. Serological analysis of the anterior chamber fluid (ACF) failed to demonstrate local antibody production to HSV or CMV, but a Goldmann-Witmer coefficient of 3.3 (normally Ͻ3) between ACF and serum anti-Toxoplasma antibodies was in favor of an active toxoplasma retinitis. PCR analysis of the ACF confirmed this diagnosis. In the meantime MRI scanning of the cerebrum unveiled several circumscript lesions with ring enhancement after intravenous gadolinium contrast, fitting a diagnosis of toxoplasmic encephalitis. Again, CSF analysis was performed and this time it was also PCR positive for toxoplasma. Treatment was switched to pyrimethamine and sulfadiazine, although this latter drug had to be switched to high-dose clindamycine intravenously, because of severe gastrointestinal complaints.
Within 5 days her mental state improved and the retinitis resolved rapidly. After 2. months of anti-toxoplasma therapy, clindamycine was switched to clarithromycine because of a presumed toxicodermic reaction. She then had a visual acuity of 0.4/0.4 and was functioning well. In February 1996, 7 months after the diagnosis of toxoplasma retinitis/encephalitis, erythema exsudativa multiforme developed: histologically the differential diagnosis between an adverse drug reaction or chronic GVHD could not be clarified. Immunosuppressive therapy was increased and anti-toxoplasmic therapy was interrupted and changed to azithromycin monotherapy. Soon the toxoplasma encephalitis progressed rapidly and she died in September 1996, 2 years after BMT and 15 months after the initial diagnosis of toxoplasma retinitis/encephalitis.
Discussion
In BMT patients, a diagnosis of toxoplasmosis is associated with a high mortality and in many reported cases the diagnosis is only made during autopsy. 2 In the present case, PCR and antibody analysis of CSF and CT scanning of the cerebrum initially failed to give a diagnosis of toxoplasmosis, but PCR and antibody analysis of the ACF, together with MRI scanning of the cerebrum, appeared to be of an important additional support, as has been discussed earlier. 4 The role of PCR was controversial in our case. Initially PCR analysis of CSF was negative, while a second sample of CSF taken 10 days later turned out to be PCRpositive. PCR findings must be interpreted with caution as previously reported. 5, 6 The incidence of reactivated toxoplasmosis in BMT patients has been calculated to be 2% in BMT patients who have a positive serostatus for toxoplasmosis pre-BMT. 2, 3 In our own series of 415 allogeneic BMT patients, (179(43%) were toxoplasma IgG seropositive pre-BMT) we have encountered two other patients with a post-mortem diagnosis of toxoplasma encephalitis, giving a total incidence of 1.6% in seropositive recipients. Next to a positive serostatus pre-BMT, severe GVHD combined with intensified immunosuppression and negative serostatus of the donor are established risk factors for toxoplasma reactivation; [1] [2] [3] all were present in our patient. Trimethoprim-sulphamethoxazole is generally believed to protect against toxoplasma reactivation in immunocompromised hosts and the fact that our patient received this prophylactic drug for only a short period of time might have been an additional risk factor in this case.
The most common presentations of toxoplasmosis in BMT patients are encephalitis, pneumonitis and myocarditis which almost always occur within 6 months after BMT.
1-3 Retinitis has been described in only two other cases 7, 8 and as in the present case can have a rather late onset post-BMT; in one case retinitis developed 161 days post-BMT, 7 in the other after 9 months. 8 In presenting this case we emphasize the possibility of toxoplasma retinitis as a very late disease manifestation in BMT recipients.
